Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 17/20 | 0.67 |
| ▸ | PPARA | Q07869 | 17/20 | 0.67 |
| ▸ | PPARD | Q03181 | 4/20 | 0.67 |
| ▸ | PGR | P06401 | 1/20 | 0.49 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.49 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.49 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.49 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.49 |
| ▸ | PDE4A | P27815 | 1/20 | 0.49 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.49 |
| ▸ | DRD3 | P35462 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6555767 | 0.99 | PPARG (0.68) | PPARGPPARAPPARD | |
| SCHEMBL7004808 | 0.98 | PPARG (0.67) | PPARGPPARAPPARDPGRADORA3 | |
| SCHEMBL7006234 | 0.98 | PPARG (0.67) | PPARGPPARAPPARDPGRADORA3 | |
| SCHEMBL7006236 | 0.93 | PPARG (0.59) | PPARGPPARAPPARD | |
| Lithium Ion SCHEMBL7004812 | 0.93 | PPARG (0.59) | PPARGPPARAPPARD | |
| Tromethamine SCHEMBL7004271 | 0.93 | PPARG (0.60) | PPARGPPARAPPARDPGRADORA3 | |
| N-Benzylmethylamine SCHEMBL7002290 | 0.93 | PPARG (0.60) | PPARGPPARAPPARD | |
| SCHEMBL6555809 | 0.92 | PPARA (0.58) | PPARGPPARAPPARDPGRADORA3 | |
| Guanidine SCHEMBL7008284 | 0.92 | PPARG (0.59) | PPARGPPARAPPARDPGRADORA3 | |
| Imidazole SCHEMBL7005117 | 0.91 | PPARG (0.58) | PPARGPPARAPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1363913-A2 | SALTS OF PYRIMIDINE DERIVATIVES FOR USE AGAINST CORONARY HEART DISEASE AND ATHEROSCLEROSE | Dr. Reddy's Laboratories Ltd. (IN) | 2003-11-26 | — | — | EP | claimed |
| US-20020169175-A1 | Pharmaceutically acceptable salts of heterocyclic compounds | DR. REDDY'S LABORATORIES LTD. | 2002-11-14 | — | — | US | claimed |
| WO-2002062798-A2 | SALTS OF PYRIMIDINE DERIVATIVES FOR USE AGAINST CORONARY HEART DISEASE AND ATHEROSCLEROSE | DR. REDDY'S LABORATORIES LTD. (IN) | 2002-08-15 | — | — | WO | claimed |
| EP-1363913-A2 | SALTS OF PYRIMIDINE DERIVATIVES FOR USE AGAINST CORONARY HEART DISEASE AND ATHEROSCLEROSE | Dr. Reddy's Laboratories Ltd. (IN) | 2003-11-26 | — | — | EP | disclosed |
| US-20020169175-A1 | Pharmaceutically acceptable salts of heterocyclic compounds | DR. REDDY'S LABORATORIES LTD. | 2002-11-14 | — | — | US | disclosed |
| WO-2002062798-A2 | SALTS OF PYRIMIDINE DERIVATIVES FOR USE AGAINST CORONARY HEART DISEASE AND ATHEROSCLEROSE | DR. REDDY'S LABORATORIES LTD. (IN) | 2002-08-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020169175-A1 | Pharmaceutically acceptable salts of heterocyclic compounds | CYP3A43, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CYP2D6 | PPARG 549/4885PPARA 1237/4885PPARD 399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.